April 2018

Merck’s Keytruda (Pembrolizumab) showed better results than chemotherapy at improving overall survival among first-line patients with non-small cell lung cancer in a trial whose results were published last Monday. The benefit extended across PD-L1-positive patients in the study, regardless of their level of PD-L1 expression.  Keytruda is the first...

AstraZeneca’s Tagrisso has been approved by FDA as a first-line treatment for patients with metastatic non-small-cell lung cancer characterized by epidermal growth factor receptor (EGFR) mutations. Tagrisso is already approved in the US as a second-line treatment for this subgroup of lung cancer patients, whose disease...